10.1016/j.actbio.2018.11.052 127
But here's what it misses: the clinical translation gap differs dramatically between the two
GLP-1 and GIP receptors are distributed throughout the body, including the pancreas, gastrointestinal tract, cardiovascular system, and central nervous system
Other long-term trials designed to evaluate whether SGLT2 inhibitors have renal protective effects in participants with T2D, and without T2D but with or without chronic kidney disease and macroalbuminuria are ongoing (e.g., the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) study, NCT02065791
These include: Intravesical dimethyl sulfoxide (DMSO): DMSO, a naturally occurring compound, has demonstrated efficacy in reducing IC symptoms in clinical trials